Salem Bio-Time to Market

After the subscription of new shares is completed, it usually takes 8- 14 days (natural day) to go public. According to the calculation, the listing time of Sailun Bio 688 163 may be from March 8 to March 14, which means that the new shares can be listed about 6 days after the lottery. Of course, the listing will be delayed after the lottery, but generally it will not exceed 65433. After the new shares are won, investors only need to ensure that there are enough subscription funds in their accounts, and then wait patiently for about 7 days before the new shares can be officially listed and traded.

I. Company Profile:

Founded in 1999, the company is a biomedical enterprise focusing on antiserum and antitoxin, focusing on the research, development, production and sales of preventive and therapeutic drugs for biotoxins and biosafety.

Second, operational risk.

Safety risks of (1) antiserum antitoxin products

The company's main products, such as anti-venom serum, mabu immunoglobulin and anti-rabies serum, are all based on the plasma produced by horse immunity, and on the basis of these plasmas, the products are finally produced through a series of biological reactions by using technologies such as efficient virus inactivation, optimization of pepsin digestion process conditions and modern column chromatography purification. In the production process, the company took isolation screening measures from the beginning of horse purchase, screened the raw plasma for related pathogens, and adopted virus inactivation technology. However, because some known or unknown human and animal pathogens were not completely inactivated in time and the residual pathogens were not detected in time, there were still product safety risks.

(2) Price reduction risk caused by product price control or competing products competition.

20 15 In May, the National Development and Reform Commission, together with the State Health Planning Commission and Ministry of Human Resources and Social Security, issued the Notice on Printing and Distributing Opinions on Promoting Drug Price Reform. Since June 20 15, the price control measures for most drugs have been abolished. Prior to this, the price of the company's antivenom products had not been adjusted for many years. 2065 438+06-2065 438+08, the company adjusted the price of antivenom products, with a large increase.

2017-20211-6 months, taking Agkistrodon halys venom as an example, the average selling prices were 574.68 yuan/stick, 945. 17 yuan/stick, 993.08 yuan/stick and 988 yuan/stick respectively. The increase in the sales price of antivenom products is one of the important factors for the company's performance growth. In the future, if the national or local authorities introduce a price limit policy for the company's anti-venom serum products, resulting in a decline in the sales price of the products, or competitive price reduction due to the emergence of competing products by new participants, the company will face the risk of slowing down its performance growth or reducing its profitability.

Among the company's main products, antivenom products have no competitive similar or substitute products in China; Immunoglobulin "ma bu" or horse stance just look is facing the competition from tetanus antitoxin and tetanus human immunoglobulin.

During the reporting period, the company's main business income mainly came from antivenom and horse-breaking immunoglobulin products. In the future, if the exclusive position of the company's anti-venom serum products in China is broken, or the market competition faced by the horse-breaking immunoglobulin is further intensified, the price of the company's main products may drop or the market share may decrease, which will adversely affect the company's performance.